• Strong revenue growth of 63% to $390.4M driven by Illuccix® and RLS acquisition
• Increased investment in R&D to $81.6M to accelerate late-stage therapeutic pipeline
• Expanded manufacturing and supply chain capabilities through RLS acquisition

Telix Pharmaceuticals Limited reported its H1 2025 results, with the company delivering strong revenue growth of 63% to $390.4 million. This was driven by continued growth in Illuccix® sales as well as the acquisition of RLS Radiopharmacies, which contributed $79.0 million in third-party product and service revenue. The company's gross margin was 53%, reflecting the change in product mix following the RLS acquisition and the inclusion of lower-margin SPECT imaging products. Telix increased its investment in R&D to $81.6 million, with a focus on advancing late-stage therapeutic assets such as the ProstACT Global Phase 3 trial for TLX591 and progressing other pipeline candidates including TLX250, TLX101, and TLX66. The company also made progress on its next-generation radiopharmaceutical programs, including TLX592, TLX252, and TLX102. Telix recorded a net loss of $2.3 million for the half-year, which included $12.4 million in non-cash interest costs related to convertible bonds issued in 2024. The company's cash balance at the end of June 2025 was $207.2 million, with positive net operating cash flow consistently delivered. Overall, Telix continues to execute on its strategy of advancing its therapeutic and diagnostic portfolio, strengthening its supply chain and manufacturing capabilities, and driving innovation.

Telix provided no high-importance, price-sensitive forward-looking financial guidance in the announcement.

Telix did not provide a specific outlook statement in the announcement, but the company highlighted its focus on accelerating the development of its late-stage therapeutic pipeline, expanding its manufacturing and supply chain capabilities, and driving innovation across its radiopharmaceutical programs.